Longitudinal registry of people with multiple system atrophy in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter registry study conducted in China to describe the clinical features and progression of multiple system atrophy (MSA) and to identify factors linked to prognosis. It will collect data from in-person visits, medical records, standardized scales, autonomic testing, imaging, labs, and biospecimens, with follow-up at predefined intervals. The study will also include Parkinson's disease patients and healthy controls for comparative analyses. Participants include adults aged 40–75 meeting MSA or PD criteria, alongside controls, with follow-up that may alternate between in-person and telephone assessments. The goal is to establish a long-term cohort to inform biomarker validation and future clinical trial design.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
2. Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
3. Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
4. Age between 40 and 75 years.
5. Ability to provide informed consent or availability of a legally authorized representative when applicable.

Exclusion Criteria

1. Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.
2. Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.
3. Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.
4. Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.
5. Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.
6. Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Zhaoxia Wang, MD — Department of Neurology, Peking University First Hospital
• Study coordinator: Yunchuang Sun, MD
• Email: sychuang0805@163.com

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized magnetic brain stimulation for parkinsonian disorders

  This study will try personalized repetitive transcranial magnetic stimulation (rTMS) to see if it eases motor and non-motor symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07570212

• Using AI to find facial and speech signs of Parkinson's and related disorders

  This project uses AI to analyze facial expressions and speech to try to find digital markers that help diagnose and tell apart Parkinson's disease, PSP, MSA, and healthy people.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07392411

• Implanting nerve tissue into the brain for Parkinson's and Multiple System Atrophy

  This study is testing if implanting nerve tissue into the brains of people with early-stage Parkinson's or Multiple System Atrophy can help repair damaged cells and slow down the disease.

  Recruiting Phase 1 University of Kentucky · Lexington, Kentucky · NCT06683365

• Collecting data on neurodegenerative diseases progression markers

  This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.

  Recruiting IRCCS San Raffaele Roma · Cassino, Frosinone · NCT06596746

• Evaluating a new PET imaging agent for brain conditions

  This study is testing a new imaging agent to see if it can help detect certain brain changes in people with Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy Bodies, as well as in healthy individuals.

  Recruiting Early Phase 1 Massachusetts General Hospital · Charlestown, Massachusetts · NCT06098612

• Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder

  This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07882108

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.